Anti-Human Siglec-3/CD33 Reference Antibody (Lintuzumab, RUO) (HB185026)

Name: Anti-Human Siglec-3/CD33 Reference Antibody (Lintuzumab, RUO)
Brand: abinScience
SKU: HB185026
Price: 176 USD
Availability: InStock

데이터시트 제품 공유 정보 복사

가격(USD):

사양:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

수량:

문의하기

개요
이미지
참고 문헌
데이터시트
SDS

개요

카탈로그 번호	HB185026
설명	Lintuzumab (HB185026) is a research-grade recombinant antibody targeting CD33. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
종 반응성	Human
응용 분야	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
숙주 종	Human
클론성	Monoclonal
이소타입	IgG1-kappa
발현 시스템	Mammalian cells
타겟	Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3
내독소 수준	< 10 EU/mg
순도	>95% purity as determined by SDS-PAGE.
정제	Protein A/G purified from cell culture supernatant.
등록번호	P20138
형태	Liquid
저장 완충액	0.01M PBS pH 7.4 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요.
안정성 및 저장	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
대체 이름	225Ac-lintuzumab, HuM195, SGN-33, SMARTM195, HuM195, 166089-32-3
배경	Myeloid cell surface antigen CD33 is a ~39 kDa protein. Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state. Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans. Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK. These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2. In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules. CD33 is the therapeutic target of gemtuzumab ozogamicin (Mylotarg). 1. Vitale, C. et al. (1999) Proceedings of the National Academy of Sciences of the United States of America 96, 15091-6. PMID: 10611343 2. Vitale, C. et al. (2001) Proceedings of the National Academy of Sciences of the United States of America 98, 5764-9. PMID: 11320212 3. Lajaunias, F. et al. (2005) European journal of immunology 35, 243-51. PMID: 15597323 4. Freeman, SD. et al. (1995) Blood 85, 2005-12. PMID: 7718872 5. Paul, SP. et al. (2000) Blood 96, 483-90. PMID: 10887109 6. Son, M. et al. (2017) Scientific reports 7, 270. PMID: 28325905 7. Taylor, VC. et al. (1999) The Journal of biological chemistry 274, 11505-12. PMID: 10206955 8. Ulyanova, T. et al. (1999) European journal of immunology 29, 3440-9. PMID: 10556798
참고사항	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Anti-LASV GPC Recombinant Antibody (Fab 37.7) (VK453013) Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)